Core Insights - *ST Changyao (300391.SZ) released its semi-annual report for 2025, indicating a total of 70.55 million shares held by institutional investors, representing 20.14% of the company's total share capital [1] - The proportion of shares held by institutional investors increased by 0.58 percentage points compared to the previous quarter [1] Institutional Holdings - As of August 25, 2025, four institutional investors disclosed their holdings in *ST Changyao A-shares [1] - The institutional investors include Changxing Shengshi Fenghua Business Co., Ltd., Shanghai Yucong Asset Management Co., Ltd. - Yucong Tianshun No. 2 Private Securities Investment Fund, Shouguang Kangyue Investment Co., Ltd., and Shanghai Kaishuang Private Fund Management Co., Ltd. - Kaishuang Gongga No. 7 Private Securities Investment Fund [1]

Core Points - The company reported a total operating revenue of 70.575 million yuan, a year-on-year decrease of 4.18%, while the net profit attributable to shareholders was -116.3538 million yuan, an increase of 23.74% year-on-year [3][4] - The decline in operating revenue is primarily attributed to financial constraints leading to decreased income in the pharmaceutical sector [3] - The increase in net profit is mainly due to a reduction in provisions for bad debts and goodwill impairment [3] Pharmaceutical Manufacturing Business - The pharmaceutical manufacturing segment achieved operating revenue of 22.5831 million yuan, a year-on-year decrease of 41.29%, with a net profit of -127.3724 million yuan, an increase of 36.59% year-on-year [4] - The significant revenue decline is due to poor accounts receivable collection and slow development in traditional Chinese medicine [4] - The company entered pre-restructuring procedures, and related creditors ceased interest accrual, leading to reduced financial expenses and initial stabilization of losses [4] Photovoltaic Business - The photovoltaic segment reported operating revenue of 47.9919 million yuan, a year-on-year increase of 36.39%, with a net profit of -13.7125 million yuan, a decrease of 9.87% year-on-year [4] - The revenue growth is attributed to the completion and sale of a production line that generated 23.11 million yuan [4] - The decline in profit is due to a prolonged downturn in the photovoltaic industry, insufficient demand, and intense price competition leading to reduced gross margins [4]

Core Viewpoint - The financial performance of Changjiang Pharmaceutical Holdings Co., Ltd. in the first quarter of 2025 shows a significant decline in revenue and net profit, indicating ongoing financial difficulties and potential risks related to its operations and restructuring efforts [1][5][6]. Financial Data Summary - **Revenue**: The company's operating revenue for the first quarter of 2025 was ¥45,795,675.76, a decrease of 22.50% compared to ¥59,091,762.31 in the same period last year [1][9]. - **Net Profit**: The net profit attributable to shareholders was -¥60,812,317.13, reflecting a decline of 28.01% from -¥47,505,902.27 in the previous year [1][10]. - **Cash Flow**: The net cash flow from operating activities was -¥71,835,780.49, a decrease of 118.90% compared to -¥32,816,721.93 in the previous year, indicating reduced cash inflows from sales [1][11]. - **Total Assets**: As of the end of the reporting period, total assets amounted to ¥2,042,496,723.36, an increase of 2.34% from ¥1,995,717,642.12 at the end of the previous year [1][8]. - **Equity**: The equity attributable to shareholders was -¥493,652,976.34, down 14.05% from -¥432,840,659.21 at the end of the previous year [1][9]. Changes in Financial Indicators - **Operating Costs**: The operating costs for the first quarter were ¥106,127,907.23, up from ¥89,749,307.79 in the previous year, indicating increased expenses despite lower revenue [9]. - **Financial Expenses**: Financial expenses surged by 181.54% to ¥34,973,280.67, primarily due to interest provisions related to ongoing litigation [1][9]. - **Credit Impairment Losses**: Credit impairment losses decreased by 32.04% to -¥31,953,818.21, suggesting improved management of accounts receivable [1][10]. Shareholder Information - **Major Shareholders**: The top ten shareholders include Changxing Shengshi Fenghua Business Co., Ltd. with a 5.99% stake and Shanghai Yucong Asset Management Co., Ltd. with a 5.05% stake [2][3]. - **Shareholder Changes**: The total number of ordinary shareholders at the end of the reporting period was 20,224, with no preferred shareholders reported [2][3]. Other Important Matters - **Restructuring Efforts**: The company is undergoing restructuring due to significant financial losses and has faced legal challenges, including lawsuits and asset freezes [5][6]. - **Going Concern Issues**: There are substantial uncertainties regarding the company's ability to continue as a going concern, with a significant accumulated loss and negative net assets reported [5][6].

Core Viewpoint - The company has corrected accounting errors in its Q1 2025 financial report, specifically affecting revenue and cost figures, but these corrections do not impact overall profit or the balance sheet [1][2][4]. Accounting Error Correction - The company held a board meeting on August 22, 2025, to approve the correction of accounting errors in the Q1 2025 financial report, following relevant accounting standards and disclosure rules [1][4]. - The correction involved changing the recognition of certain trade transactions from "gross method" to "net method" based on the principle of prudence [1][2]. Financial Impact - The correction affects the following financial metrics for Q1 2025: - Total operating revenue was adjusted from 103,683,885.34 CNY to 45,795,675.76 CNY, a decrease of 57,888,209.58 CNY [2][3]. - Total operating costs were adjusted from 164,016,116.81 CNY to reflect the same decrease in revenue [2][3]. - The adjusted operating revenue shows a year-on-year decrease of 22.50%, attributed to a decline in the pharmaceutical segment's income [3]. Independent and Audit Committee Opinions - The independent directors and audit committee have reviewed the corrections and agree that they comply with relevant regulations, enhancing the accuracy and quality of the financial information [4][5]. Future Measures - The company emphasizes its commitment to improving the quality of information disclosure and plans to enhance training for financial personnel to prevent similar issues in the future [4].

Group 1 - The core point of the article is that *ST Changyao announced a board meeting to address accounting errors in the first quarter financial report for 2025 [1] - For the first half of 2025, *ST Changyao's revenue composition is 68.0% from the photovoltaic industry and 32.0% from the pharmaceutical industry [1] - As of the report, *ST Changyao has a market capitalization of 1.5 billion yuan [1]

格隆汇8月25日丨*ST长药(300391.SZ)公布半年度报告，公司报告期实现营业收入7,057.50万元，同比减 少4.18%，归属于上市公司股东的净利润-11,635.38万元，同比增加23.74%；公司报告期内营业收入同比 减少，主要原因是因资金紧张医药板块收入下降；归属于上市公司股东的净利润同比增加，主要原因是 本期计提应收账款、商誉减值准备减少。 ...

长江医药控股股份有限公司 长江医药控股股份有限公司董事会 编制单位：长江医药控股股份有限公司 金额单位：人民币万元 2025年8月26日 | | | 湖北新峰制药有 | 子公司 | 其他应 | 122.18 | 12.64 | 2.27 | 96.34 | 40.75 | 资金 | 非经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 湖北长江丰医药 | 子公司 | 其他应 | 104.14 | 0 | 0 | 104.14 | 0 | 资金 | 非经营 | | | | 有限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 湖北明月和医药 | 子公司 | 其他应 | 6.95 | | 0.20 | | 7.15 | 资金 | 非经营 | | | | 科技有限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 恩施明群健康医 药产业科技有限 | 子公司 | 其他应 ...

2、本次计提信用减值准备、资产减值准备的资产范围和总金额 证券代码：300391 证券简称：*ST 长药 公告编号：2025-085 长江医药控股股份有限公司 关于2025年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 22 日召开的第六届董事会第二次会议审议通过了《关于 2025 年半年度计提 资产减值准备的议案》。依据《深圳证券交易所创业板股票上市规则》等法律法 规相关规定，具体如下： 一、本次计提信用减值准备、资产减值准备情况 （一）本次计提信用减值准备、资产减值准备情况概述 1、本次计提信用减值准备、资产减值准备的原因 公司本次计提信用减值准备、资产减值准备，是依照《企业会计准则》及公 司会计政策的相关规定进行的。公司对截至 2025 年 6 月 30 日各类资产进行了全 面清查，并对各类资产进行了充分的评估和分析，本着谨慎性原则，公司需对可 能发生减值损失的相关资产进行计提减值准备。 公司对截至 2025 年 6 月 30 日存在可能发生减 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-086 长江医药控股股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、日常关联交易基本情况 （一）预计2025年度日常关联交易的基本情况 为充分拓展销售渠道，发挥相关方资源优势，促进公司产品销售，实现较好 经济效益，根据业务经营发展需要，长江医药控股股份有限公司（以下简称"公 司"）控股子公司湖北长江星医药股份有限公司（以下简称"长江星"）及/或其 子公司2025年度预计与公司关联法人湖北凤源春武当道茶生物科技有限公司（以 下简称"凤源春"）及其关联方因销售产品、商品发生日常关联交易，关联交易 总额预计不超过人民币2000万元（含税）。 公司于2025年8月22日召开了第六届董事会第二次会议，审议通过了《关于 2025年度日常关联交易预计的议案》，关联董事翁浩、赵守军回避表决。本议案 经公司第六届董事会独立董事第一次专门会议审议通过。本次关于2025年度日常 关联交易预计的事项未达到股东会审批标准。 （二）预计日常关联交易类别和金额 单 ...

证券代码：300391 证券简称：*ST长药 公告编号：2025-087 长江医药控股股份有限公司 重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告嘉兴骏鹰仓实投资合伙企业(有限合伙)与被告长江医药控股股份有限 公司、第三人湖北长江大药房连锁有限公司债权人代位权纠纷案，十堰市中级人 民法院于2025年8月15日判决。本案涉案金额18,947.85万元，涉及的82.13万元 预计将对公司当期损益产生影响。 一、诉讼事项的基本情况 2025年8月21日，长江医药控股股份有限公司（以下简称"公司"）收到湖 北省十堰市中级人民法院送达的判决书。湖北省十堰市中级人民法院所在地为十 堰市张湾区浙江路66号。诉讼各方当事人如下： 原告：嘉兴骏鹰仓实投资合伙企业(有限合伙)，委派代表张程程；委托诉讼 代理人陈宇、曾若霖，湖北楚阳律师事务所律师。 被告：长江医药控股股份有限公司，法定代表人胡士会；委托诉讼代理人周 郎惠，湖北汉丰律师事务所律师。 第三人：湖北长江大药房连锁有限公司，法定代表人阳勇；委托诉讼代理人 周浩，广东盛兆冠獬律师事务所 ...